jtt 501 has been researched along with Hyperglycemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, VS; Ramaa, CS; Vora, DK | 1 |
| Matsui, K; Shibata, T; Wakitani, K; Yonemori, F | 1 |
1 review(s) available for jtt 501 and Hyperglycemia
| Article | Year |
|---|---|
Thiazolidine-2,4-diones: progress towards multifarious applications.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Antineoplastic Agents; Arthritis, Rheumatoid; Bacterial Infections; Drug Design; Enzyme Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Mycoses; Neoplasms; PPAR gamma; Structure-Activity Relationship; Thiazolidinediones | 2013 |
1 other study(ies) available for jtt 501 and Hyperglycemia
| Article | Year |
|---|---|
JTT-501, a novel oral antidiabetic agent, improves insulin resistance in genetic and non-genetic insulin-resistant models.
Topics: Animals; Blood Glucose; Disease Models, Animal; Glucose; Glucose Clamp Technique; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Isoxazoles; Leptin; Lipids; Male; Obesity; Oxidation-Reduction; Phosphorylation; Proteins; Rats; Rats, Sprague-Dawley; Rats, Zucker; Receptor, Insulin; Triglycerides | 1998 |